This page lists the SEC filings reported by Novo Holdings A/S.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2017-06-15 | Novo A/S | REATA PHARMACEUTICALS INC | 2,994,763 | 18.3% | EDGAR |
| SC 13G/A | 2017-05-09 | Novo A/S | iRhythm Technologies, Inc. | 0 | 0.0% | EDGAR |
| SC 13G | 2017-05-09 | Novo A/S | Verona Pharma plc | 14,159,611 | 14.0% | EDGAR |
| SC 13D/A | 2017-04-20 | Novo A/S | CoLucid Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2017-03-31 | Novo A/S | HTG MOLECULAR DIAGNOSTICS, INC | 1,280,185 | 15.9% | EDGAR |
| SC 13D/A | 2017-03-10 | Novo A/S | HTG MOLECULAR DIAGNOSTICS, INC | 1,280,185 | 18.1% | EDGAR |
| SC 13D/A | 2017-03-03 | Novo A/S | Apollo Endosurgery, Inc. | 1,456,972 | 13.6% | EDGAR |
| SC 13D/A | 2017-03-03 | Novo A/S | REATA PHARMACEUTICALS INC | 3,367,763 | 20.7% | EDGAR |
| SC 13D/A | 2017-03-03 | Novo A/S | Merus N.V. | 1,410,417 | 8.8% | EDGAR |
| SC 13G/A | 2017-02-08 | Novo A/S | Invuity, Inc. | 1,318,448 | 7.8% | EDGAR |
| SC 13G/A | 2017-02-08 | Novo A/S | Inogen Inc | 3,549,320 | 17.5% | EDGAR |
| SC 13G/A | 2017-02-08 | Novo A/S | Nabriva Therapeutics AG | 232,655 | 8.6% | EDGAR |
| SC 13G | 2017-02-08 | Novo A/S | iRhythm Technologies, Inc. | 2,024,448 | 9.1% | EDGAR |
| SC 13D | 2017-01-04 | Novo A/S | Apollo Endosurgery, Inc. | 1,456,972 | 13.6% | EDGAR |
| SC 13D/A | 2016-12-19 | Novo A/S | Ophthotech Corp. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2016-12-09 | Novo A/S | REATA PHARMACEUTICALS INC | 3,367,763 | 29.7% | EDGAR |
| SC 13D | 2016-11-30 | Novo A/S | KalVista Pharmaceuticals, Inc. | 2,901,927 | 29.2% | EDGAR |
| SC 13D | 2016-11-03 | Novo A/S | Ra Pharmaceuticals, Inc. | 2,031,562 | 9.5% | EDGAR |
| SC 13D/A | 2016-09-14 | Novo A/S | CoLucid Pharmaceuticals, Inc. | 3,156,563 | 17.0% | EDGAR |
| SC 13G/A | 2016-08-10 | Novo A/S | Tobira Therapeutics, Inc. | 173,905 | 0.9% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.